Intradetrusor Botulinum toxin type A (BTX-A) injection has emerged as a novel therapeutic option for the treatment of idiopathic overactive bladder (I-OAB) refractory to oral antimuscarinic agents. We designed an IRB approved prospective trial to evaluate the improvement in urinary frequency (UF) and urge urinary incontinence (UUI) using voiding diaries (VD), urodynamic findings, validated symptomatic improvement, and quality of life in I-OAB patients submitted to a scheduled re-injection BTX-A protocol. For the Full Story:®_repeated_injections_outcome_data_using_voiding_diaries_and_udi6_correlation.html